drug_type
RELEVANT_DRUG
intervention_type
radiopharmaceutical (radioisotope)
drug_description
A beta- and gamma-emitting radionuclide used as a radiopharmaceutical label; when conjugated to NY108, it enables SPECT imaging of biodistribution and delivers targeted beta radiation to PSMA-expressing tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Lutetium Radioisotopes
drug_category
RADIOIMMUNOCONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Lutetium-177, a beta- and gamma-emitting radionuclide, is chelated to the anti-PSMA monoclonal antibody NY108. After binding PSMA on tumor cells and being internalized, it delivers short-range beta radiation that induces DNA damage and tumor cell death, while gamma emissions enable SPECT imaging of biodistribution.
drug_name
Lutetium-177
nct_id_drug_ref
NCT05815394